-

Best’s Market Segment Report: Underwriting Conditions for UAE Insurers on Track to Improve Amid IFRS 17 Transition

LONDON--(BUSINESS WIRE)--Measures put in place by the United Arab Emirates (UAE) insurance regulator, the Central Bank of the UAE, during 2023 and in early 2024 should ameliorate the relatively poor performance of personal lines insurance and support premium growth in the country, according to a new report from AM Best.

The Best’s Market Segment Report, “Underwriting Conditions for UAE Insurers on Track to Improve Amid IFRS 17 Transition,” notes that continued regulatory intervention was important given that the underwriting profitability of the UAE’s listed insurers continued to be affected by the heightened competitive environment in the motor and medical segments.

In the report, AM Best analysts also examine the recently published results for the UAE’s listed insurers and discuss the impact of the transition to the new IFRS 17 reporting regime.

To access a complimentary copy of this special report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=342283.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2024 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Todor Kitin, ACA
Financial Analyst
+44 20 7397 0335
todor.kitin@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Richard Banks
Director, Industry Research – EMEA
+44 20 7397 0322
richard.banks@ambest.com

Edem Kuenyehia
Director, Market Development & Communications – EMEA & AP
+44 20 7397 0280
edem.kuenyehia@ambest.com

AM Best


Release Versions
Hashtags

Contacts

Todor Kitin, ACA
Financial Analyst
+44 20 7397 0335
todor.kitin@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Richard Banks
Director, Industry Research – EMEA
+44 20 7397 0322
richard.banks@ambest.com

Edem Kuenyehia
Director, Market Development & Communications – EMEA & AP
+44 20 7397 0280
edem.kuenyehia@ambest.com

Social Media Profiles
More News From AM Best

AM Best Assigns Credit Ratings to Charp Re, Ltd.

MEXICO CITY--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb” (Good) to Charp Re, Ltd. (Charp Re) (Turks & Caicos Islands). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Charp Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management (ER...

AM Best Revises Outlooks to Positive for FMH Insurance Group’s Members

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Farmers Mutual Hail Insurance Company of Iowa and its reinsured affiliate, FMH Ag Risk Insurance Company. Both companies are domiciled in West Des Moines, IA and are collectively referred to as FMH Insurance Group (FMH).The Credit Ratings (ratings) reflect FMH’s overall balance sheet str...

Best’s Commentary: Health Insurers Evaluating Balance Between Pharmacy Costs and Long-Term Value of GLP-1 Therapies

OLDWICK, N.J.--(BUSINESS WIRE)--As pharmacy cost trends continue to rise and clinical evidence evolves, health insurers face a fundamental question on whether improvements in long-term morbidity and the potential for improved mortality outcomes ultimately justify significant investments in GLP-1 therapies, according to a new AM Best commentary. The Best’s Commentary, “GLP-1 Therapies: Evaluating the Balance Between Pharmacy Costs and Long-Term Value,” states that GLP-1 therapies have become one...
Back to Newsroom